Investigation of Pazopanib and Human Serum Albumin Interaction Using Spectroscopic and Molecular Docking Approaches

Pazopanib (PAZ), a tyrosine kinase inhibitor, is used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). The FDA approved PAZ for RCC in 2009 and for STS in 2012. The antitumor activity of pazopanib, according to the degree of inhibition, shows different results dep...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ahmet Cetinkaya, Mehmet Gokhan Caglayan, Mehmet Altay Unal, Pinar Beyazkilic, Caglar Elbuken, Esen Bellur Atici, Sibel A. Ozkan
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-03-01
Edice:	Analytica
Témata:	pazopanib human serum albumin fluorescence spectroscopy circular dichroism molecular docking
On-line přístup:	https://www.mdpi.com/2673-4532/3/1/11
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!